TOKYO, Apr 27 (Pulse News Wire) – Astellas Pharma Inc. (4503.T) announced today that its board of directors has approved changes to the company's executive lineup, which will take effect following approval at the 21st annual shareholders’ meeting scheduled for June 19, 2026.
Key appointments include the reappointment of Yasukawa Kenji as Chairman, Okamura Naoki as President and CEO, and Sugita Katsuyoshi as Deputy President responsible for human resources. Additionally, Takahara Shigeki, currently serving as CFO at Kansai Electric Power Company, will join the board as an external director and audit committee member. Notably, three external directors—Tanaka Takashi, Sakurai Eriko, and Nakayama Mika—are set to retire.
The revised board structure post-shareholder approval will consist of internal and external directors, including international executives such as Andreas Busch from BioMarin Pharmaceutical Inc. and Mark Enyedy from Charles River Laboratories International, Inc. Takahara Shigeki’s career highlights include roles at NEC Corporation, Nippon Telegraph and Telephone Corporation, and Pfizer, among others, culminating in his position as CFO at Kansai Electric Power Company until July 2025, followed by consultancy work thereafter.
His expertise in finance and operations will bolster Astellas' strategic direction moving forward.
🟡 Confidence: Standard AI-translated content.